Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report
The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.
Authors
- А. L. Kornietskaya (ORCID: https://orcid.org/0000-0003-0092-0459)
- Л. В. Болотина (ORCID: https://orcid.org/0000-0003-4879-2687)
- А. А. Феденко (ORCID: https://orcid.org/0000-0003-4927-5585)
- А. Д. Каприн (ORCID: https://orcid.org/0000-0001-8784-8415)
- S. F. Evdokimova (ORCID: https://orcid.org/0000-0002-1993-3842)
- Iliya V. Kolobayev
Institutions
- Peoples' Friendship University of Russia (RU)
- Ministry of Health of the Russian Federation (RU)
- P.A. Hertzen Moscow Oncology Research Institute (RU)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.3389/fonc.2024.1494669
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00